Related Experiment Videos
Receptor-targeted immunotherapy
Bulletin on the Rheumatic Diseases
|January 1, 1992
Summary
Novel receptor-targeted immunotherapies, including monoclonal antibodies and immunotoxins, show promise for treating human diseases. Further clinical trials are essential to evaluate these advanced genetic engineering techniques, potentially in combination with traditional medications.
Area of Science:
- Immunology
- Biotechnology
- Pharmacology
Background:
- Genetic engineering advances have enabled the creation of novel receptor-targeted immunotherapies.
- These therapies aim to modulate immune and inflammatory responses for treating various human diseases.
Purpose of the Study:
- To review and discuss emerging receptor-targeted immunotherapies developed through modern genetic engineering.
- To highlight the potential applications and the need for further clinical evaluation of these novel treatments.
Main Methods:
- Review of current literature on receptor-targeted immunotherapies.
- Description of specific approaches such as monoclonal antibodies (mAbs) targeting T cell subsets (CD4+, CD5+), immunotoxins, diphtheria toxin-IL-2 conjugates, T cell receptor (TCR) antibodies, IL-1 receptor antagonists, and soluble receptors for IL-1 and TNF.
Main Results:
- Several novel receptor-targeted immunotherapies have been developed using genetic engineering.
- These include therapies targeting specific cell surface receptors and cytokines involved in immune and inflammatory processes.
Conclusions:
- Emerging receptor-targeted immunotherapies present promising avenues for treating human diseases.
- Rigorous clinical evaluation is crucial for these novel approaches, with potential for synergistic effects when combined with conventional anti-inflammatory and immunosuppressive drugs.